Lilly’s Next Obesity Blockbuster Retatrutide on Track for 2027 Approval After Five Positive Phase 3 Studies

Analysts say Lilly’s retatrutide, heading for 2027 FDA filing after strong trials, could hit $3.8B sales by 2030 and help keep its edge over Novo Nordisk.